argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$960.04−21.29 (-2.17%)
Close on Nov 13, 2026Market cap –P/E 49.1Yield –
argenx cash
Cash and short-term investments held at the end of each period.
argenx's cash was $3.58B at Jun 30, 2026. For fiscal 2025 it was $3.49B, up 132.7% from the year before. The highest annual figure on record is $3.49B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.49B | +132.7% |
| FY2024 | Dec 31, 2024 | $1.50B | -26.8% |
| FY2023 | Dec 31, 2023 | $2.05B | +155.9% |
| FY2022 | Dec 31, 2022 | $800.74M | -40.0% |
| FY2021 | Dec 31, 2021 | $1.33B | +9.7% |
| FY2020 | Dec 31, 2020 | $1.22B | +227.0% |
| FY2019 | Dec 31, 2019 | $372.16M | +15.7% |
| FY2018 | Dec 31, 2018 | $321.79M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.58B | +149.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.49B | +70.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.09B | +87.8% |
| Q4 FY2024 | Dec 31, 2024 | $1.50B | +87.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.44B | +5.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.05B | +53.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.11B | -29.8% |
| Q4 FY2022 | Dec 31, 2022 | $800.74M | -34.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.37B | +1.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.33B | +258.6% |
| Q2 FY2021 | Jun 30, 2021 | $1.58B | +391.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.22B | – |
| Q2 FY2020 | Jun 30, 2020 | $1.35B | – |
| Q4 FY2019 | Dec 31, 2019 | $372.16M | – |
| Q4 FY2018 | Dec 31, 2018 | $321.79M | – |
See a number that looks wrong?